Send to

Choose Destination
Hosp Pharm. 2014 Oct;49(9):813-25. doi: 10.1310/hpj4909-813.

Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.

Author information

Department of Pharmacy, The Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute , Columbus, Ohio.
The University of Arizona Cancer Center, The University of Arizona , Tucson, Arizona.
Department of Clinical, Social and Administrative Sciences, University of Michigan Health System , Ann Arbor, Michigan.
Scientific Affairs, Amgen Inc. , Thousand Oaks, California .


Pharmacists will play a key role in evaluating biosimilars for formulary inclusion in the United States. As defined by US law, a biosimilar is a biologic that is highly similar to its reference product, notwithstanding minor differences in clinically inactive components, and should not have clinically meaningful differences from its reference product in safety, purity, and potency. We review biosimilars and the current European Union and US regulatory pathways for biosimilars. Furthermore, we propose a checklist of considerations to ensure that US pharmacists thoroughly evaluate future biosimilars for formulary inclusion. Included in the checklist are considerations related to the availability of preapproval and postapproval safety and efficacy data; differences in product characteristics and immunogenicity between the biosimilar and reference product; manufacturer-related parameters that can affect a reliable supply of quality products; health-system and patient perspectives on product packaging, labeling, storage, and administration; costs and insurance coverage; patient education; interchangeability and differences in the range of indications; and evaluation of institutions' information technology systems.


biologics; biosimilars; formulary; pharmacovigilance; reference product

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center